Skip to main content
NHS Scotland Logo
Right Decision Service: supporting decisions for Scotland's health and care
Healthcare Improvement Scotland Logo
  • Right Decisions
  • All resources
  • Organisations
  • Topics
  • Learning & support
  • How to deliver RDS tools
  • Feedback
  1. Right Decisions
  2. Back
  3. NHS Borders drugs and therapeutics
  4. Anticoagulation

Anticoagulation

NHS Borders drugs and therapeutics
NHS Borders

Antithrombotic Guideline - NHS Borders

Anticoagulation Bridging for Patients with Severe Renal Impairment or End Stage Renal Disease

Apixaban in DVT / PE in NHS Borders – treatment protocol

Apixaban for the management of suspected DVT in the community

Apixaban: prophylaxis of stroke and systemic embolism

Apixaban Switch Protocol

Elective Surgery Guideline : Low Molecular Weight Heparin, Warfarin, Direct Oral Anticoagulant and Anti-Platelet Management

Extended Venous Thromboembolism (VTE) Prophylaxis for orthopaedic patients - NHS Borders

Extended Venous Thromboembolism (VTE) Prophylaxis for Surgical Patients undergoing Major Abdominal or Pelvic Surgery for Cancer - NHS Borders

Heparin – adult infusion chart

Management of bleeding with dabigatran

Rapid reversal of rivaroxaban and apixaban with andexanet alfa in life/limb threatening bleeding

Reversal of Warfarin (Oral)

VTE Extended prophylaxis for surgical patients undergoing major abdominal or pelvic surgery for cancer in NHS Borders

Warfarin initiation

Right Decision Service: supporting decisions for Scotland's health and care

  • The Right Decision Service: Scotland's national decision support platform
  • Terms and conditions of your use of the Right Decisions Platform (RDP)
  • Content provider terms and conditions of use of the Right Decisions Platform (RDP)
  • Accessibility & browser/device compatibility
  • Using screen readers
  • Equality and Human Rights Impact Assessment (EQIA)

Downloads

  • Download the app on the Apple store
  • Download the app on the Google Play store

Powered by QURIS v7.20.5 © 2026.
Back to the top